Sylvester Comprehensive Cancer Center

  • 20220603 - Byrnes Diana

  • Investigator:
    Diana Byrnes
    RCname Email

    Coordinator:

    IRB: 20220603

    SDG: Benign Heme
    Disease Site(s):

    Multiple

    Sponsor: Anthos Therapeutics

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancerassociated VTE (ASTER)

    Eligibility Criteria - NCT05171049 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231020 - Soff Gerald

  • Investigator:
    Gerald Soff
    RCname Email

    Coordinator:

    IRB: 20231020

    SDG: Benign Heme
    Disease Site(s):

    Breast,Ovary

    Sponsor: AMGEN

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    PROCLAIM: 20170770: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer

    Eligibility Criteria - NCT03937154 *This information has been extracted from " www.clinicaltrials.gov"